An unoccluded oxybutynin gel formulation for topical application comprising: a therapeutically effective amount of oxybutynin; and 0.05 wt.% to 10 wt.% of a gel carrier selected from; a) polyacrylic acids of poly(1-carboxythylene), carboxypolymethylenes prepared from acrylic acid cross"-linked with allyl ethers of (polyalkyl) sucrose or pentaerythritol, carbamer polymers, sodium acrylate polymers, other polycarboxylic acids, alkyl acrylate polymers and mixtures or copolymers thereof, b) carboxyvinyl polymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl methyl ether, polyvinyl ether, polyvinyl sulfonates, and mixtures or copolymers thereof, c) polyethylene compounds, polysaccharides and salts thereof, acryclic acid esters, alkoxybutynin polymers, polyoxyethylene-polyoxypropylene copolymers, polyethylene oxide polymers, polyethers, gelatin succinate, colloidal magnesium aluminum silicate, petroleum jelly and mixtures or copolymers thereof, d) hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, hydroxypropylbutyl cellulose, hydroxypropylpentyl cellulose, hydroxyethyl cellulose, ethylcellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose phthalate and cellulose acetate, or e) dextran, gaur-gum, tragacanth, xanthan gum, sodium alginate, sodium pectinate, sodium laginate, acacia gum, Irish moss, karaya gum, guaiac gum, locust bean gum, casein, gelatin, collagen, albumin, globulin, fibrin, cellulose, dextrin, pectin, starches, agar and mannan; and at least 40 wt.% of a solvent selected from lower alcohols, ethanol, isopropanol, benzyl alcohol, propanol, methanol, other C 4 -C 10 mono-alchohols and mixtures thereof; wherein: the formulation has a pH or from 4 to 11; the oxybutynin is present as a pharmaceutically acceptable oxybutynin salt; the formulation is prepared for unoccluded topical application to a skin surface; which upon topical administration proves an oxybutynin plasma concentration of at least 0.5 ng/ml within at least 3 hours after administration and below 8 ng/ml at 24 hours after administration; and which upon unoccluded topical administration reduces and/or minimizes adverse drug experiences associated with oxybutynin therapy. a therapeutically effective amount of oxybutynin; and 0.05 wt.% to 10 wt.% of a gel carrier selected from; a) polyacrylic acids of poly(1-carboxythylene), carboxypolymethylenes prepared from acrylic acid cross"-linked with allyl ethers of (polyalkyl) sucrose or pentaerythritol, carbamer polymers, sodium acrylate polymers, other polycarboxylic acids, alkyl acrylate polymers and mixtures or copolymers thereof, b) carboxyvinyl polymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl methyl ether, polyvinyl ether, polyvinyl sulfonates, and mixtures or copolymers thereof, c) polyethylene compounds, polysaccharides and salts thereof, acryclic acid esters, alkoxybutynin polymers, polyoxyethylene-polyoxypropylene copolymers, polyethylene oxide polymers, polyethers, gelatin succinate, colloidal magnesium aluminum silicate, petroleum jelly and mixtures or copolymers thereof, d) hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, hydroxypropylbutyl cellulose, hydroxypropylpentyl cellulose, hydroxyethyl cellulose, ethylcellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose phthalate and cellulose acetate, or e) dextran, gaur-gum, tragacanth, xanthan gum, sodium alginate, sodium pectinate, sodium laginate, acacia gum, Irish moss, karaya gum, guaiac gum, locust bean gum, casein, gelatin, collagen, albumin, globulin, fibrin, cellulose, dextrin, pectin, starches, agar and mannan; and a) polyacrylic acids of poly(1-carboxythylene), carboxypolymethylenes prepared from acrylic acid cross"-linked with allyl ethers of (polyalkyl) sucrose or pentaerythritol, carbamer polymers, sodium acrylate polymers, other polycarboxylic acids, alkyl acrylate polymers and mixtures or copolymers thereof, b) carboxyvinyl polymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl methyl ether, polyvinyl ether, polyvinyl sulfonates, and mixtures or copolymers thereof, c) polyethylene compounds, polysaccharides and salts thereof, acryclic acid esters, alkoxybutynin polymers, polyoxyethylene-polyoxypropylene copolymers, polyethylene oxide polymers, polyethers, gelatin succinate, colloidal magnesium aluminum silicate, petroleum jelly and mixtures or copolymers thereof, d) hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, hydroxypropylbutyl cellulose, hydroxypropylpentyl cellulose, hydroxyethyl cellulose, ethylcellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose phthalate and cellulose acetate, or e) dextran, gaur-gum, tragacanth, xanthan gum, sodium alginate, sodium pectinate, sodium laginate, acacia gum, Irish moss, karaya gum, guaiac gum, locust bean gum, casein, gelatin, collagen, albumin, globulin, fibrin, cellulose, dextrin, pectin, starches, agar and mannan; and at least 40 wt.% of a solvent selected from lower alcohols, ethanol, isopropanol, benzyl alcohol, propanol, methanol, other C 4 -C 10 mono-alchohols and mixtures thereof; the formulation has a pH or from 4 to 11; the oxybutynin is present as a pharmaceutically acceptable oxybutynin salt; the formulation is prepared for unoccluded topical application to a skin surface;